BiOptic, an emerging biotech stock listed on the Emerging Stock Board, held a board meeting on the 24th to approve its 2024 financial report and earnings distribution plan. The company reported a consolidated revenue of NT$202 million for last year, down 11% year-over-year, and a net income after tax of NT$22.73 million, representing a 40% annual decrease. Earnings per share (EPS) stood at NT$0.76. Taking into account the company's steady business development and growth stage, the board resolved to distribute a surplus dividend of NT$1.3 per share, including a cash dividend of NT$0.3 and a stock dividend of NT$1.
Read more
